Intra-arterial Bevacizumab for Posterior Fossa Hemangioblastoma

Hemangioblastoma (HB) is a rare, highly vascularized, and benign central nervous system (CNS) tumor. This vascularity is due to a high degree of signaling by vascular endothelial growth factor (VEGF). Consequently, anti-VEGF agents, such as bevacizumab, have been postulated and shown in a few cases...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokol, Zachary, Hoeft, Ava, Kung, David, Belman, Neil, Oselkin, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Radiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841884/
https://www.ncbi.nlm.nih.gov/pubmed/36654589
http://dx.doi.org/10.7759/cureus.32624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841884/
https://www.ncbi.nlm.nih.gov/pubmed/36654589
http://dx.doi.org/10.7759/cureus.32624

Ejemplares similares